USA: Neoadjuvant Chemo Boosts Structure Preservation Rates in Nasal, Sinus Cancer
Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b resectable nasal and paranasal sinus squamous cell carcinoma (NPNSCC) requiring orbital or skull base resection, according to a study presented at the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
Nabil F. Saba, M.D., from Winship Cancer Institute of Emory University in Atlanta, and colleagues reported the SP analysis in a study involving patients with T3, T4a, and selected T4b resectable NPNSCC. Participants were randomly allocated to receive surgery followed by postoperative radiation therapy of 60 Gy (standard arm) or the same treatment preceded by three cycles of neoadjuvant docetaxel 75 mg/m2 and cisplatin 75 mg/m2 (experimental arm). The SP rate and overall survival were the co-primary objectives.
Source: Advances and More licensed by HealthDay
